Johnson & Johnson (NYSE:JNJ) had its target price boosted by equities research analysts at Citigroup Inc. from $140.00 to $149.00 in a research note issued on Monday. The brokerage currently has a “buy” rating on the stock. Citigroup Inc.’s price objective would indicate a potential upside of 3.75% from the company’s current price.

Several other equities analysts also recently commented on the company. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the company an “outperform” rating in a research report on Thursday. Jefferies Group LLC boosted their target price on Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, October 16th. Barclays PLC boosted their target price on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 18th. Cowen and Company reiterated an “outperform” rating and issued a $155.00 target price (up from $147.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Finally, Morgan Stanley reiterated a “hold” rating and issued a $145.00 target price (up from $140.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and an average target price of $142.07.

Shares of Johnson & Johnson (JNJ) traded up 0.86% during trading on Monday, reaching $143.62. The company’s stock had a trading volume of 6,685,964 shares. The company has a 50 day moving average of $134.13 and a 200 day moving average of $130.97. The company has a market cap of $385.48 billion, a PE ratio of 24.98 and a beta of 0.78. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $144.35.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.68% and a net margin of 21.28%. The business had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. During the same period in the previous year, the business earned $1.68 earnings per share. The business’s revenue was up 10.3% on a year-over-year basis. On average, analysts anticipate that Johnson & Johnson will post $7.27 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) PT Raised to $149.00 at Citigroup Inc.” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/23/johnson-johnson-jnj-pt-raised-to-149-00-at-citigroup-inc.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in JNJ. Harding Loevner LP bought a new position in shares of Johnson & Johnson during the second quarter valued at approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its stake in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after buying an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. grew its stake in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after buying an additional 5 shares during the last quarter. IHT Wealth Management LLC grew its stake in shares of Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after buying an additional 3,467 shares during the last quarter. Finally, Mountain Capital Investment Advisors Inc bought a new position in shares of Johnson & Johnson during the second quarter valued at approximately $124,000. 65.90% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.